Clinical Trial Search

Primary: The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85…

Primary: Overall Pain Responder Rate — 36; 34 Participants

Primary: Percentage of Participants With Objective Response Rate Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing…

Primary: BB % Relative Dose (Mean) With Regard to Target Dose — 56.29; 71.09 percentage of target dose — p=<0.001

Primary: Level of Pain — .39; .19; .14; .56 units on a scale

Primary: Clinical Assessment Interview for Negative Symptoms (CAINS) — .0667; -.0588 score on a scale

Primary: Number of Patients With Adverse Events — 5; 2; 5; 2 participants

Primary: Change From Baseline in Trough FEV1 at Week 12 — -0.013; -0.031; 0.062; 0.099 Liters — p=0.437

Primary: ACR50 (American College of Rheumatology 50% Improvement) Response at Week 12 — 7.1; 26.8; 41.5; 46.3 percentage of subjects — p==0.031

Primary: tDCS Engagement of DLPFC Activity Indexed by fMRI BOLD Imaging

Primary: Number of Patients With Serious Bleeding Events — 0; 1 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 91; 31; 26 Participants

Primary: Percentage of Participants With a Solicited Injection-site Adverse Event After Vaccination 1 — 4.6; 3.3; 57.2; 51.3 Percentage of Participants

Primary: Morphine Equivalents — 8.3; 7.5 MEU

Primary: AUC Fluticasone Propionate (FP) — 188.2; 756; 978; 380.5 pg.h/ml — p=<0.05